About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Y
ADAURA Trial: Impact of Adjuvant Osimertinib on CNS Disease Recurrence in NSCLC
By
Yi-Long Wu
247 views
September 9, 2021
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
18:47
Total Health
Updates in the Management of NSCLC: Systemic Therapy Year in Review
Feat.
W. Iams
35:40
Balazs Halmos
Year in Review: Lung Cancer
11:07
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical…
Feat.
J. West
26:21
Memorial Sloan Kettering Cancer Center
NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…
Feat.
M. Hwang
14:49
Vivek Subbiah
Year in Review: Precision Medicine
23:32
2023 West Oncology Conference
2023 Updates on Neoadjuvant and Adjuvant NSCLC
Feat.
M. Johnson
54:26
Yale Cancer Center
Year in Review: Progress in NSCLC Treatment
Feat.
R. Herbst
17:34
ecancer
Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…
Feat.
L. Raez
20:27
Yale Cancer Center
Progress in the Treatment of NSCLC
Feat.
R. Herbst
08:30
Insights from 2023 ESMO Annual Meeting
PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EG…
Feat.
N. Girard
26:42
Total Health
ADAURA & KEYNOTE-671 Trials: Early Stage NSCLC Updates - 2023 AS…
Feat.
J. Bauman
08:15
ecancer
ESMO 2023 Summary: "Highlights From Recent NSCLC Trials"
Feat.
B. Gyawali
23:29
2023 Evolution Conference
IO and Targeted Treatment for mNSCLC
Feat.
M. Mooradian
07:38
GRACE
How Does PD-L1 Score Affect Treatment Options for NSCLC
Feat.
S. Patel,
T. Leal,
P. Iyengar,
A. Desai,
C. Kim,
J. Rotow
03:22
ecancer
WCLC 2023 Insights: "Phase 3 FLAURA2 Study - Osimertinib + Chem…
Feat.
P. Janne
04:31
Integrity Continuing Education
Neoadjuvant and Adjuvant Treatment in Early Stage NSCLC: Options Are…
Feat.
J. Gainor,
J. Sands
28:04
OncoAlert
Current Controversies in NSCLC Treatment
Feat.
J. West
20:28
OncoAlert
mNSCLC Updates: 1L EGFRm, 2/3L EGFRm & Anti-Trop2 ADC
Feat.
C. Aggarwal
14:31
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage
Placing ADCs in the Lung Cancer Treatment Algorithm
Feat.
J. Reuss
13:21
Yale Cancer Center
Navigating the Terrain: Recent Treatment Strategies for EGFRm Advanc…
Feat.
A. Nassar